Huntington Disease: Clinical Features and Diagnosis
UptoDate Dec 2017, Oksana Suchowersky, 2017
Huntingtons Disease
BMJ 341:34-40, Novak,M.J. &Tabrizi,S.J., 2010
Predictors of Nursing Home Placement in Huntington Disease
Neurol 60:998-1001, Wheelock,V.L.,et al, 2003
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Clinicopath Conf
Huntington's Diseae, Case2-1992, NEJM 326:117-125992., , 1992
Tetrabenazine Therapy of Dystonia, Chorea, Tics, & Other Dyskinesias
Neurol 38:391-394, Jankovic,J.&Orman,J., 1988
The Gait Abnormality of Huntington's Disease
Neurol 35:1450-1454, Koller,W.C.&Trimble,J., 1985
Neurotransmitters & CNS Disease, Basal Ganglia Disease
Lancet 2:1141-1147, Marsden,C.D., 1982
Huntington's Chorea-Deficiency of Y-Aminobutynic Acid in Brain
NEJM 288:337, 1973, 289:104, 1973, 292:10295., Perry,T.,et al, 1975
Clinical Diagnosis of the Dyskinesias
Med Clin of North Am 56:1321, Duvoisin,R., 1972
Diseases of the Extrapyramidal System
Disease-a-month-Jan 1970., Klawans,H.,et al, 1970
Huntington's Chorea
Bruyn, G. W. In Vinken & Bruyn, Handbk of Clin Neurol, North-Holland Publ Co, Amsterdam, 6:298, , 1968
Diseases of the Basal Ganglia-Their Relation to Disorders of Movement
Lancet 1099, 1960, Nov., Denny-Brown,D., 1960
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease
Neurol 79:597-603, Armstrong, M.J. & Miyasaki, J.M., 2012
Predictors of Diagnosis in Huntington Disease
Neurol 68:1710-1717, Langbehn,D.R.,et al, 2007
Neural Transplantation in Huntington Disease: Long-Term Grafts in Two Patients
Neurol 68:2093-2098, Keene,C.D.,et al, 2007
Psychiatric Disorders in Preclinical Huntingtons Disease
JNNP 78:939-943, Julien,C.L.,et al, 2007
Tetrabenazine as Antichorea Therapy in Huntington Disease, A Randomized Controlled Trial
Neurol 66:366-372, Huntington Study Group, 2006
The Association of CAG Repeat Length with Clinical Progression in Huntington Disease
Neurol 66:1016-1020, Rosenblatt,A.,et al, 2006
Saccades in Presymptomatic and Early Stages of Huntington Disease
Neurol 67:394-399, Blekher,T.,et al, 2006
Identification of an Oculomotor biomarker of Preclinical Huntington Disease
Neurol 67:485-487, Golding,C.V.P.,et al, 2006
Effect of Donepezil on Motor and Cognitive Function in Huntington Disease
Neurol 67:1268-1271, Cubo,E.,et al, 2006
Functional Brain Changes in Presymptomatic Hunington's Disease
Ann Neurol 55:879-883, Reading,S.A.,et al, 2004
Prenatal Diagnosis Requests for Huntington's Disease when the Father is at Risk, and Does Not Want to Know His Genetic Status: Clinical, Legal, and Ethical Viewpoints
BMJ 326:331-333, Tassicker,R.,et al, 2003
Intoxication with Riluzole in Huntington's Diease
Neurol 57:1141-1143, Bodner,Th.,et al, 2001
Family History and DNA Analysis in Patients With Suspected Huntington's Disease
JNNP 69:54-59, Siesling,S. et al, 2000
Predictive Testing for Huntington's Disease: the Calm After the Storm
Lancet 356:1944-1945, Hayden,M.R., 2000
Motor and Cognitive Improvements in Patients with Huntington's Disease after Neurol Trasnplantation
Lancet 356:1975-1979,1945, Bachoud-Levi,A.,et al, 2000
iH NMR Spectroscopy Studies of Huntington's Disease, Correlations with CAG Repeat Numbers
Neurol 50:1357-1365, Jenkins,B.G.,et al, 1998
Patients with Features Similar to Huntington's Disease, Without CAG Expansion in Huntingtin
Neurol 51:215-220, Rosenblatt,A.,et al, 1998
Few Psychological Consequences of Presymptomatic Testing for Huntington Disease
Lancet 349:4, Bundey,S., 1997
CAG Repeat Number Governs the Development Rate of Pathology in Huntington's Disease
Ann Neurol 41:689-692, Penney,J.B.,et al, 1997
Genetic Testing of Children at Risk for Huntington's Disease
Neurol 49:1048-1053, Nance,M.A.,et al, 1997
Relationship Between Trinucleotide Repeats and Neuropathological Changes in Huntington's Disease
Ann Neurol 39:132-136, Furtado,S.,et al, 1996
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Trinucleotide Repeat Length and Clinical Progression in Huntington's Disease
Neurol 46:527-531, Brandt,J.,et al, 1996
Psychiatric Symptoms Do Not Correlate with Cognitive Decline, Motor Sympt or CAG Repeat Length in Huntington's
Arch Neurol 53:493-497, Zappacosta,B.,et al, 1996
Motor Changes in Presymptomatic Huntington Disease Gene Carriers
Arch Neurol 53:487-492, Siemers,E.,et al, 1996
Diagnosis of Patients Presenting to a Huntington Disease (HD) Clinic without a Family History of HD
Neurol 47:1578-1580, Nance,M.A.,et al, 1996
Hereditary Late-Onset Chorea Without Significant Dementia:Genetic Evid for Phenotypic Variation in Huntington's Disease
Neurol 45:443-447, Britton,J.W.,et al, 1995
Correlations Between Triplet Repeat Expansion and Clinical Features in Huntington's Disease
Arch Neurol 113:749-753, Claes,S.,et al, 1995
The Prevention of Neurogenetic Disease
Arch Neurol 52:356-362, 3451995., Rosenberg,R.N.&Iannaccone,S.T., 1995
The Neurogenetic Genie:Testing for Huntington's Disease Mutation
Neurol 44:1369-1373, 1533-15361994., Hersch,S.,et al, 1994
CAG Repeat Size and Clinical Presentation in Huntington's Disease
Neurol 44:1137-1143, Ashizawa,T.,et al, 1994
A Worldwide Study of the Huntington's Disease Mutation, The Sensitivity & Specificity of Measuring CAG Repeats
NEJM 330:1401-1406, 14501994., Kremer,B.,et al, 1994
Clozapine in Huntington's Chorea
Neurol 44:821-823, Bonuccelli,U.,et al, 1994
Reduced Basal Ganglia Volume Associated with the Gene for Huntington's Disease in Asymptomatic at-Risk Persons
Neurol 44:823-828, Aylward,E.H.,et al, 1994
Trinucleotide Repeat Length and Rate of Progression of Huntington's Disease
Ann Neurol 36:630-635, Illarioshkin,S.N.,et al, 1994